## SYNTHESIS OF 1,11a-ETHANO CORTICOSTEROIDS

P. Wieland and J. Kalvoda\*

Research Laboratories, Ciba-Geigy Pharmaceuticals Division 4002 Basel, Switzerland


ABSTRACT: lla-Formyl-methyl derivative 5 of prednisolone has been reductively cyclized to give the versatile pentacyclic intermediates 7 and 9 of novel 1,lla-ethano-bridged corticosteroid analogues.

Two different effects are thought to be responsible for the positive influence of a  $9\alpha$ -fluoro atom on the biological activity of corticosteroids <sup>1,2</sup>: The fluorine stabilizes the reduced (llB-hydroxy) active form of the drug in comparison to the oxidized (ll-oxo) inactive one <sup>3</sup>, at the same time inducing a stronger bending of ring A, thereby generating a special arrangement which might be closer to the biologically active conformation.

Attempts to obtain a similar effect by introducing a methyl group into the lla-position have failed <sup>4</sup>. Compounds containing a tertiary llB-hydroxy group were shown to be inactive. These negative results, however, could be attributed to additional steric interactions between C(1) and the lla-methyl group, unfavourably influencing the conformation of the molecule. To test this hypothesis, we endeavoured to exclude the possible interaction by bridging C(1) and C(11) of hydrocortisone and prednisolone with a C<sub>2</sub> unit <sup>5</sup>. Simultaneously, ring A of the planned compounds of type I (Scheme 1) could be fixed in specific chosen conformations, depending on the configuration and/or hybridization of C(1). We report here on a stereoselective synthesis of this novel class of pentacyclic steroids <sup>6</sup>.

The crucial step in our approach consisted in the reductive ring-closure of a keto-aldehyde (II) via an intermediate dianionic species III  $^7$ . The necessary intermediate of type II was prepared as depicted in Scheme 2. The protected cortisone derivative 1  $^8$  was first transformed to the






lla-dimethallyl carbinol 2 <sup>9</sup> (59 %; F: 154-156°). After deprotection at C(3) (82 %; F: 181-183°), the resulting compound 3 was dehydrogenated via the corresponding 2-phenylselenyl derivative to yield the  $a^{1,4}$ -3-ketone 4 (55 %; F: 194-197°). By subsequent ozonization, the desired aldehyde 5 (82 %; F: 212-213°) was obtained.

Treatment of 5 with lithium and diphenyl in THF<sup>10</sup> as a source of radical anions generated, as expected <sup>11</sup>, the two epimeric diols <u>7a</u> (5.5 %; F: 208-248°) <sup>12</sup> and <u>9a</u> (25.5 %; F: 267.5-272°)<sup>13</sup>. In addition, the secoketone  $6^{-14}$  (5.2 %; F: 234-238°) was formed. Both diols were oxidized (CrO<sub>3</sub>/H<sub>2</sub>SO<sub>4</sub>/acetone/O°) to the same hydroxydiketone <u>7b</u> (F: 269-272°). The configurations of the chiral centers at C(1) and C(1)' of <u>7</u> and <u>9</u> were deduced from mechanistic considerations and the physical properties of these compounds. Subsequent transformations established the correctness of the assumed stereochemistry at C(1).

Compound <u>7a</u> was selectively mesylated at the equatorial 1'-hydroxy group and the crude mesylate <u>7c</u> treated (18 hrs.) with NaOAc in AcOH at 80°. The 17-side-chain of the isolated monool <u>10</u> (F: 243-258° dec.) was deprotected and the 21-hydroxy group of the free ethanoprednisolone directly esterified yielding the corresponding 21-propionate <u>11</u> (F: 213-219°). The same compound was obtained starting from the epimeric 1'3-mesylate <u>9b</u> (F: 151-153°) by subsequent deprotection of the side-chain and propionylation (<u>8</u>), followed by elimination of methane sulfonic acid using the above procedure. When LiBr/Li<sub>2</sub>CO<sub>3</sub>/DMF was used instead of NaOAc/AcOH, the non-conjugated dienone <u>12</u> (F:204-206°) was obtained. The structures of <u>11</u> and <u>12</u> were confirmed by X-ray analyses <sup>15</sup>.







## References and Notes

- 1. c.f. I.E. Bush and V.B. Mahesh, Biochem.J. 93, 236 (1964).
- W.L. Duax, Ch.M.Weeks and D.C. Rohrer, Recent Progress Hormon Research <u>1976</u>, 102.
- A. Eschenmoser and J. Schreiber (personal communication) studied the kinetics of the oxidation steroidal of 9,11-halohydrins in comparison to 9-unsubstituted 11B-hydroxy compounds, thereby confirming the predicted behaviour of 9a-fluoro derivatives.
- R.E. Beyler, F. Hoffman and L.H. Sarett, J.Amer.Chem.Soc. <u>82</u>, 178 (1960);
  G. Anner (Ciba-Geigy) unpublished experiments.
- Biologically interesting compounds containing an oxygen bridge between C(1) and C(11) will be described in a forthcoming paper (J. Kalvoda, J. Grob and U. Joss, Helv.Chim. Acta <u>67</u> [1984] in preparation.
- Aromatic pentacyclic steroid analogues have recently been synthesized by T.S. Bhatt, M.M. Coombs, A.-M. Kissonerghis, A.F.D. Clayton and M. McPartlin (J.C.S. Chem.Commun. <u>1979</u>, 433); C.G. Pitt, J.Chem.Soc.Perkin Trans. I, <u>1977</u>, 1144.
- Qualitative MO arguments (high-lying HOMO ["filled LUMO"] of the dianion and low-lying LUMO of the carbonyl group) seem to favour the envisaged process.
- 8. J.H. Fried, G.E. Arth and L.H. Sarett, J.Amer.Chem.Soc. 81, 1235 (1959).
- All new compounds described in this communication gave satisfactory analyses and spectral data compatible with the proposed structure. The mps are uncorrected.
- H.L. Dryden, G.M. Webber and J.J. Wieczorek, J.Amer.Chem.Soc. <u>86</u>, 742 (1964).
- 11. C.f. also P. Wieland and G. Anner, Helv.Chim.Acta 51, 1932 (1968).
- 12. The long and different melting points of several samples of <u>7a</u> could be explained by the presence of varying small amounts of the loH-epimer.
- 13. On treatment of the much more stable 17,20,20,21-bismethylendioxy-lla-hydroxy-pregna-1,4-dien-3-one acetate with lithium in ammonia, M. Tanabe et al <sup>14</sup> were able to isolate a compound formed by uncleophilic attack of a carbanion at C<sub>1</sub> similar to the one depicted in III on the acetate carbonyl group.
- M. Tanabe, J.W. Chamberlin and P.Y. Nishiura, Tetrahedron Letters <u>1951</u>, 601.
- 15. For detailed X-ray data and biological behaviour of the new 1,11 bridged corticosteroids, c.f. P. Wieland, G. Rihs and J. Kalvoda, Helv.Chim.Acta <u>67</u>, (1984) in preparation.

(Received in Germany 20 September 1983)